Glycogen storage disease type IV can be complicated by cardiac arrhythmia, a manifestation that requires individualized clinical evaluation and a carefully selected therapeutic strategy.
This protocol addresses patients with glycogen storage disease type IV who present with cardiac arrhythmia. Given the limited published data in this population, management decisions should be individualized in collaboration with clinical electrophysiologists.
Antiarrhythmic therapy is a component of management in this setting. The full protocol details the specific agents and the individualization framework — see the complete regimen below.
DOI: 10.1016/j.ymgme.2023.107525
Successful treatment of arrhythmias with β-blockers and sotalol have been reported; however, antiarrhythmic should be individualized to the specific patient in consultation with clinical electrophysiologists given the limited data available.
View source ↗